Researchers at Georgia Regents University will study a product derived from marijuana that could be used to treat children who suffer from seizures, under a new agreement between the university, the state and a pharmaceutical company.

Epidolex is a GW Pharmaceuticals investigational product that uses cannabidiol, a marijuana extract also known as CBD that doesn't get users high, university officials said in a written statement Tuesday.

The plan for the state university study came after lawmakers failed to pass a bill during the 2014 session allowing limited medical use of cannabidiol in Georgia.

GW Pharmaceuticals Chairman Geoffrey Guy said Georgia Regents University, which is home to the Medical College of Georgia, has the experience, expertise and infrastructure to launch the study with the scientific and regulatory standards in mind.

Read More